Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

Unraveling the impact of pathological Tau phosphorylations on the early Tau interactome in Alzheimer's disease

Tau-Stick2Me

The Tau protein during Alzheimer's disease (AD) becomes hyperphosphorylated, misfolds, and aggregates into neurofibrillary tangles (NFTs). Despite knowing the involvement of Tau in AD, the exact mechanism that drives Tau-mediated toxicity is largely unclear. Studying the Tau interactome is an excellent way to decipher the mechanism of Tau toxicity...

Funding Programme
EU-Horizon Europe
Start Date
End Date
Total Funding
€ 216 240
European Countries Involved

Unraveling the impact of RNA-editing in neurodegeneration: a focus on TDP-43 related frontotemporal dementia.

NeuroEDIT

Age-related neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD), are a major public health problem since there is no effective treatment due to the poor understanding of the pathological processes involved in neuronal death. RNA editing, particularly A-to-I changes mediated by ADAR enzymes...

Funding Programme
EU-Horizon Europe
Start Date
End Date
Total Funding
€ 194 074
European Countries Involved

Unravelling ApoE4 contribution to tau-mediated synaptic degeneration in AD by combining advanced proteomics and super resolution microscopy

SynApoE

Alzheimers disease (AD) is one of the biggest scientific and socio-economic challenges of the 21st century. Currently, there is no cure. Aggregates of amyloid- and tau protein, along with neuroinflammation/gliosis, are hallmarks of AD that lead to synaptic and neuronal loss as the basis for cognitive decline. The latter correlates closely with the...

Funding Programme
EU-Horizon Europe
Start Date
End Date
Total Funding
€ 1 498 449
European Countries Involved

Unravelling the impact of nucleosome arrays on condensin by implementing an in-vitro chromatin-loop extrusion assay

ConNuc

The three-dimensional organization of chromosomal DNA is essential for critical genomic functions, including chromosome segregation, gene expression, and DNA damage repair. Structural Maintenance of Chromosomes (SMC) complexes, such as cohesin, the Smc5/6 complex, and condensin, are integral to preserving chromosomal architecture and supporting...

Funding Programme
EU-Horizon Europe
Start Date
End Date
Total Funding
€ 217 965
European Countries Involved

Unravelling White Matter Biological Heterogeneity for the Prediction of AD

WHY-AD

White matter (WM) is being increasingly studied in Alzheimer’s disease (AD) as a possible key pathological driver. In-vivo, WM health can be measured through several metrics derived from diffusion weighted imaging (DWI). While these metrics provide information about the WM micro- and macro-structural alterations, the biological processes...

Funding Programme
EU-Horizon Europe
Start Date
End Date
Total Funding
€ 193 643
European Countries Involved

Unveiling human astrocyte states, functions and their contribution to Alzheimer´s disease

hASTROCURE

The pathogenesis of Alzheimer´s disease (AD) is not fully understood and no cure is available so far. Current therapeutic targets are insufficient and there is an urgent need for finding new pathways and mechanisms and novel targets to treat this terrible disease. Due to critical species-specific differences and the limitations of rodent models of...

Funding Programme
EU-Horizon Europe
Start Date
End Date
Total Funding
€ 1 999 875
European Countries Involved

VELES Excellence Hub - Strengthening the South-East Europe Smart Health Regional Excellence and Boosting the Innovation Potential

VELES

Smart Health is EU Strategic Value Chain that contributes to growth, jobs and competitiveness. Health Data is the main enabler for the value chain, but it also depends on cutting edge technologies - AI, cloud computing, IoT, to integrate the dispersed knowledge and support innovative healthcare solutions and services. EC sets the creation of a...

Funding Programme
EU-Horizon Europe
Start Date
End Date
Total Funding
€ 4 750 000
European Countries Involved

Window to the brain: a game changer in the discovery of human neuronal circuitry, cellular heterogenicity and biomarker profile indicative of early Alzheimer's disease -related pathology

HUMANE

The molecular mechanisms leading to Alzheimer's disease (AD) are poorly understood. This is due to lack of human tissue samples for research representing early changes of AD pathology. The accumulating pathology, including beta-amyloid and tau proteins, are manifested by concomitant neuroinflammatory reactions geared by malfunctional microglia...

Funding Programme
EU-Horizon Europe
Start Date
End Date
Total Funding
€ 1 998 389
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).